Table 1.
Baseline characteristics of 25 patients with lipodystrophy who initiated or withdrew from metreleptin
| Clinical values | Initiation (n = 17) | Withdrawal (n = 8) |
|---|---|---|
| Type of lipodystrophy (generalized/partial) | (5/12) | (8/0) |
| Subtype of lipodystrophy | 5 CGL, 12 FPL | 7 CGL, 1 AGL |
| Sex (male/female) | (3/14) | (3/5) |
| Age (years) | 29 ± 16 | 25 ± 6 |
| Race/ethnicity | 9 White, 6 Hispanic, 1 Asian, 1 Other | 4 White, 2 African American, 2 Hispanic |
| Weight (kg) | 70.1 ± 17.3 | 59.2 ± 17.0 |
| Endogenous leptin level (ng/dL)a | 3.9 [0.6,12.8] | 1.3 [0.9,1.5] |
| Duration of metreleptin treatment prior to study (year) | 0 | 7.7 ± 4.7 |
| Patients on insulin (%) | 71% | 0 |
| Insulin dose (units/day, insulin users only) | 193 ± 130 | 0 |
| Noninsulin diabetes medications per subject (n) | 1.3 ± 1.1 | 0.4 ± 0.5 |
| Lipid medications per subject (n) | 1.8 ± 1.0 | 0.4 ± 0.7 |
Abbreviations: AGL, acquired generalized lipodystrophy; CGL, congenital generalized lipodystrophy; FPL, familial partial lipodystrophy.
a In the withdrawal cohort, endogenous leptin in fasting serum samples was measured prior to metreleptin initiation by radioimmunoassay. In the initiation cohort, endogenous leptin was measured by enzyme-linked immunosorbent assay.